Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

NCT02089737 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02089737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02089737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
June 30, 2010
Completion date
July 31, 2012
Enrollment
3,091 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or recurrent colorectal cancer